ESG Report 2025

8.3.4 Labelling and Leaflets The United Laboratories formulates and implements management systems for label-type packaging materials in accordance with legal and regulatory requirements. All drug leaflets and labels comply with the requirements of the “Regulations on the Management of Drug Leaflets and Labels” and are approved, filed or authorised by the National Medical Products Administration (NMPA). The Group has established strict internal systems to ensure that drug labels and leaflets comply with relevant regulatory requirements. Drug labels must clearly display key information such as the drug name, ingredients, indications and directions for use, dosage and administration, and date of manufacture, so that users fully understand the usage and potential risks of the drug. In addition, the Group has clear requirements for packaging labels on transport, storage and APIs, including necessary information such as the drug name, packaging quantity, expiry date, and storage and transport precautions, to reduce the risk of product quality being affected by improper storage or transport. Furthermore, drug leaflets must specify detailed information on usage, safety and efficacy data, adverse reactions, etc., to guide users in the correct and rational use of the drug. The Group continuously monitors drug usage and, when necessary, submits applications to the NMPA for modifications to drug leaflets, providing users with the most complete information. At the same time, the Group has established management procedures for the plate-making, printing and acceptance of product labels, leaflets and packaging materials. The quality management department conducts acceptance and inspection at each step, from sample design and sample plate printing to formal printing, ensuring that materials are only put into use in the workshop after confirmation of no errors, thereby minimising the possibility of product quality problems caused by printing errors. The United Laboratories strictly complies with laws and regulations such as the “Advertising Law of the People's Republic of China”, the “Drug Administration Law” and the “Anti-Unfair Competition Law”, and carries out drug promotion and sales activities in accordance with the principles of integrity, compliance and transparency. The Group has established a comprehensive marketing compliance management system. Under the leadership of the Board of Directors, the Group's Brand Culture Department provides guidance and supervision, while each subsidiary establishes a cultural publicity working group, implementing a tiered management structure to ensure that all marketing activities are legal and compliant, effectively safeguarding patient interests and corporate reputation. To standardise promotional conduct, the Group has formulated the “Sales Conduct Code” and the “Compliance Promotion Guidelines”, which provide clear behavioural guidance in areas such as academic visit exchanges, academic conference standards, speaker fees, gifts and hospitality, equipment placement, retail terminal sales, patient information protection, and donations and sponsorships. These policies draw clear compliance red lines for all sales and promotion personnel, explicitly prohibiting the sale of drugs in unauthorised locations, interference with physicians' prescribing decisions, exaggeration or concealment of adverse reaction information, improper transfer of benefits, and other misconduct. They also set specific rules on the standard for lecturer fees, the maximum value of gifts, and the collection and protection of patient information, ensuring the transparency and integrity of promotional activities. The Group's sales team covers the entire country. The recruitment, performance appraisal, training and occupational safety management of sales personnel are centrally managed and supervised by the Group's headquarters, ensuring that all managers and front-line promotion personnel receive the necessary training, thereby achieving a uniform professional standard and providing customers with the highest quality service. 8.4 Responsible Marketing 68 The United Laboratories International Holdings Limited 2025 Environmental, Social and Governance Report